8/25/2011 8:07:15 AM
Belgian biotech company ThromboGenics (THR.BR) said on Wednesday it had substantially increased investment in marketing with a view to launching its lead drug at the end of 2012. The Belgian company plans to seek regulatory approval in Europe and the United States for its eye disease treatment ocriplasmin before the end of the year. ThromboGenics said it had cash of 96.4 million euros ($135.8 million) at the end of June, compared with 61.2 million euros at the same time a year earlier.
comments powered by